Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline

J Clin Endocrinol Metab. 2018 Nov 1;103(11):4043-4088. doi: 10.1210/jc.2018-01865.

Abstract

Objective: To update the congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency clinical practice guideline published by the Endocrine Society in 2010.

Conclusions: The writing committee presents updated best practice guidelines for the clinical management of congenital adrenal hyperplasia based on published evidence and expert opinion with added considerations for patient safety, quality of life, cost, and utilization.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Hyperplasia, Congenital / diagnosis
  • Adrenal Hyperplasia, Congenital / economics
  • Adrenal Hyperplasia, Congenital / genetics
  • Adrenal Hyperplasia, Congenital / therapy*
  • Cost-Benefit Analysis
  • Endocrinology / standards*
  • Female
  • Fetal Therapies / economics
  • Fetal Therapies / methods
  • Fetal Therapies / standards
  • Genetic Counseling / economics
  • Genetic Counseling / methods
  • Genetic Counseling / standards
  • Glucocorticoids / therapeutic use
  • Humans
  • Infant, Newborn
  • Long-Term Care / economics
  • Long-Term Care / methods
  • Long-Term Care / standards
  • Neonatal Screening / economics
  • Neonatal Screening / standards
  • Patient Safety / standards
  • Quality of Life
  • Societies, Medical / standards*
  • Therapies, Investigational / economics
  • Therapies, Investigational / methods
  • Therapies, Investigational / standards

Substances

  • Glucocorticoids

Supplementary concepts

  • Congenital adrenal hyperplasia due to 21 hydroxylase deficiency